Veritas Intercontinental completes its perinatal services offering with the launch of myPrenatalWES, an innovative prenatal diagnostic test
Retrieved on:
Wednesday, September 29, 2021
CGH, Biotechnology, Down syndrome, Genetic counseling, Patau, Deletion, Diagnosis, Sex, CNV, Recurrence, Intercontinental, Veritas Genetics, Health, Fortis Healthcare, Pregnancy, MECP2 duplication syndrome, Gene, Genomics, Non-functional testing, Child, Trisomy, Leadership, Genetics, Risk, Technology, Prognosis, Chromosome, NIPT, Quality of life, Medical imaging, Birth control, Medical device
MADRID, Sept. 29, 2021 /PRNewswire/ -- Veritas Intercontinental launches myPrenatalWES, a differential prenatal diagnostic test developed for at-risk pregnancies that provides, with a single technique, an analysis of deletions and duplications (CNVs or Copy Number Variants) along with the molecular study of genes related to fetal findings.
Key Points:
- - Veritas Intercontinental expands its range of perinatal services with the launch of myPrenatalWES, an innovative prenatal diagnostic test indicated for pregnancies with risk of genetic alteration.
- - myPrenatalWES technology is a breakthrough because it allows, with a single test, to replace the different techniques used in prenatal diagnosis, shortening the response time, and maximizing the diagnostic yield.
- -Veritas opened its state-of-the-art genetics laboratory in 2020, offering perinatal services to its global partners.
- In the absence of findings, a second technique of sequencing of specific genes related to the ultrasound findings is necessary.